How to appeal a UnitedHealthcare women's health — menopause, endometriosis, pcos, ppd denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for women's health — menopause, endometriosis, pcos, ppd

Cited policy: OptumRx Prior Authorization — Veozah (Fezolinetant) for VMS

Moderate-to-severe VMS with documented frequency >=7 HF/day. Step therapy through paroxetine (Brisdelle) +/- gabapentin OR documented HT contraindication. Baseline LFTs + REMS enrollment.

How UnitedHealthcare denies women's health — menopause, endometriosis, pcos, ppd — and how to counter it

Where UnitedHealthcare pushes back: 1) Try paroxetine first; 2) Try HT first; 3) Hepatotoxicity REMS not documented; 4) Insufficient VMS severity.

Counter-arguments that hold up: SKYLIGHT-1/2 NEJM/Lancet 2023 — 63% VMS reduction. NAMS 2023 nonhormone position statement endorses fezolinetant. Document Brisdelle/gabapentin failure or HT contraindication (VTE/breast/liver). Submit baseline LFTs + REMS enrollment confirmation.

What UnitedHealthcare typically denies for women's health — menopause, endometriosis, pcos, ppd

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For women's health — menopause, endometriosis, pcos, ppd, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the women's health — menopause, endometriosis, pcos, ppd treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Veozah (hot flashes)
• Zurzuvae (PPD)
• Menopause HT
• Orilissa (endo)
• Myfembree
• Oriahnn (fibroids)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.